Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Peifer

Showing results (41-50 of 102) with videos related to

Pageof 11
Sort By:
Nature Genetics|November 16, 2021
Chromothripsis followed by circular recombination drives oncogene amplification in human cancerCarolina Rosswog, Christoph Bartenhagen, Anne Welte, et al.
JCO Precision Oncology|February 1, 2022
Telomerase Is a Prognostic Marker of Poor Outcome and a Therapeutic Target in NeuroblastomaAndrea Roderwieser, Frederik Sand, Esther Walter, et al.
Gut|May 24, 2015
Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancerMichael Kloth, Vanessa Ruesseler, Christoph Engel, et al.
Cancer Research|January 28, 2010
Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutationMartin L Sos, Haridas B Rode, Stefanie Heynck, et al.
Journal for Immunotherapy of Cancer|April 17, 2024
Germline homozygosity and allelic imbalance of HLA-I are common in esophagogastric adenocarcinoma and impair the repertoire of immunogenic peptidesMaria Alejandra Garcia-Marquez, Martin Thelen, Eugen Bauer, et al.
Cancer Research|March 3, 2025
Editor's Note: PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFRMartin L Sos, Mirjam Koker, Barbara A Weir, et al.
Cancer Research|April 9, 2009
PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFRMartin L Sos, Mirjam Koker, Barbara A Weir, et al.
British Journal of Cancer|February 22, 2023
Genomic ALK alterations in primary and relapsed neuroblastomaCarolina Rosswog, Jana Fassunke, Angela Ernst, et al.
Cell Reports|July 5, 2016
Identification and Targeting of Long-Term Tumor-Propagating Cells in Small Cell Lung CancerNadine S Jahchan, Jing Shan Lim, Becky Bola, et al.
Nature Communications|October 23, 2023
Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemiaOthman Al-Sawaf, Can Zhang, Hyun Yong Jin, et al.
Pageof 11

Showing results (41-50 of 102) with videos related to

Sort By:
Pageof 11
Nature Genetics|November 16, 2021
Chromothripsis followed by circular recombination drives oncogene amplification in human cancerCarolina Rosswog, Christoph Bartenhagen, Anne Welte, et al.
JCO Precision Oncology|February 1, 2022
Telomerase Is a Prognostic Marker of Poor Outcome and a Therapeutic Target in NeuroblastomaAndrea Roderwieser, Frederik Sand, Esther Walter, et al.
Gut|May 24, 2015
Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancerMichael Kloth, Vanessa Ruesseler, Christoph Engel, et al.
Cancer Research|January 28, 2010
Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutationMartin L Sos, Haridas B Rode, Stefanie Heynck, et al.
Journal for Immunotherapy of Cancer|April 17, 2024
Germline homozygosity and allelic imbalance of HLA-I are common in esophagogastric adenocarcinoma and impair the repertoire of immunogenic peptidesMaria Alejandra Garcia-Marquez, Martin Thelen, Eugen Bauer, et al.
Cancer Research|March 3, 2025
Editor's Note: PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFRMartin L Sos, Mirjam Koker, Barbara A Weir, et al.
Cancer Research|April 9, 2009
PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFRMartin L Sos, Mirjam Koker, Barbara A Weir, et al.
British Journal of Cancer|February 22, 2023
Genomic ALK alterations in primary and relapsed neuroblastomaCarolina Rosswog, Jana Fassunke, Angela Ernst, et al.
Cell Reports|July 5, 2016
Identification and Targeting of Long-Term Tumor-Propagating Cells in Small Cell Lung CancerNadine S Jahchan, Jing Shan Lim, Becky Bola, et al.
Nature Communications|October 23, 2023
Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemiaOthman Al-Sawaf, Can Zhang, Hyun Yong Jin, et al.
Pageof 11